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Abstract Nuclear factor loB (NF-IcB) is a transcription factor 
that is critical for the inducible expression of multiple cellular and 
viral genes. DNA binding activity is essential for its function. 
Here, we report that gold compounds, especially aurothioglucose 
(AuTG), have a strong inhibitory effect on NF-JcB-DNA binding. 
Our finding also reveals that Zn 2÷ is a necessary component of 
NF-JcB for its DNA binding activity and that gold ion can effi- 
ciently block NF-~,--DNA binding, presumably through oxida- 
tion of the cysteins associated with zinc. This redox mechanism 
may provide an explanation for the observed efficacy of gold 
compounds in the treatment of rheumatoid arthritis. 
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I. Introduction 
Nuclear factor xB (NF-xB) is an inducible cellular transcrip- 
tion factor that regulates a wide variety of cellular and viral 
genes [1,2]. These include genes for several cytokines, some cell 
adhesion molecules (CAMs), major histocompatibility antigen, 
serum amyloid A protein and a variety of viruses including 
human immunodeficiency virus (HIV) [3]. Although NF-xB is 
by no means the sole determinant for inducible xpression of 
these genes, it has been shown to play a significant role [4]. 
Previous tudies have demonstrated that NF-xB binding to the 
specific DNA sequence (called the xB motif) is essential for the 
transcriptional ctivity of these genes [5]. The induction of 
NF-xB binding is independent of new protein synthesis and 
involves dissociation of NF-xB from a cytosolic anchoring pro- 
tein, IxB, followed by translocation of NF-tcB to the nucleus 
where it activates the target genes [2]. Most of the genes known 
to be activated by NF-xB are involved in the immune and 
inflammatory responses [4,6]. In recent years, we have demon- 
strated that the DNA binding activity of NF-xB is regulated 
by an oxido-reductive mechanism (redox regulation). We found 
that oxidation of NF-xB abolished the DNA binding activity 
and that the subsequent reduction completely restored the ac- 
tivity [7,8]. These observations have indicated that development 
of a novel therapeutic strategy might be feasible by using chem- 
ical reagents that could modulate the redox status of NF-xB. 
*Corresponding author. Fax: (81) (52) 859 1235. 
Abbreviations: NF-xB, nuclear factor xB; CAMs, cell adhesion mole- 
cules; RA, rheumatoid arthritis; oPA, 1,10-orthophenanthroline; DTT, 
dithiothreitol; AuTG, aurothioglucose; DPA, D-penicillamine; AuTM, 
aurothiomalate; EMSA, electrophoretic mobility shift assay. 
In rheumatoid arthritis (RA), the involvement of constitutive 
production of high levels of several cytokines, such as inter- 
feron fl (IFN-fl), TNF-~, IL-2, IL-6, IL-8 and granulocyte- 
macrophage colony stimulating factor (GM-CSF), as well as 
expression of some CAMs, including intercellular adhesion 
molecule- 1 (ICAM- 1), mostly under the control of NF-IcB, has 
been implicated [9,10]. Gold compounds, containing elemental 
aurous gold cation, Au(I), combined with a sulfur-containing 
ligand have been widely used in the treatment of RA, although 
the precise mechanism of their actions are largely unknown 
[11]. These findings led us to investigate whether these anti-RA 
drugs might have an effect on the action of NF-lcB. 
In this paper, we examined the inhibitory effects of gold 
compounds, together with related reagents, on the DNA bind- 
ing activity of NF-xB in vitro. The possible mechanism for such 
activity is discussed. 
2. Materials and methods 
2.1. Reagents 
DEAE-Sepharose CL-6B, Heparin Sepharose CL-6B and poly(dI- 
dC) were purchased from Pharmacia (Uppsala, Sweden). 1,10- 
Orthophenanthroline (oPA), zinc chloride, cadmium chloride, copper 
chloride, gold chloride, and aurothioglucose (AuTG) were supplied by 
Sigma. Auranofin (SmithKline Beecham Pharmaceuticals, Philadel- 
phia, PA), aurothiomalate (AuTM) (Shionogi Pharmaceutical Co., 
Tokyo) and D-penicillamine (DPA) (Tokyo Kasei Co., Tokyo) were 
obtained from the respective pharmaceutical ompanies. 
2.2. Purification of NF-xB 
NF-xB was prepared from the nuclei of human primary lymphocytes 
as reported previously [7]. Briefly, the crude nuclear extract was frac- 
tionated on heparin-Sepharose and DEAE-Sepharose columns. Protein 
was eluted from DEAE-Sepharose columns by a continuous 0.05-1.0 
M KC1 gradient using the Econo System (Bio-Rad, Hercules, CA). The 
fractions with the xB DNA binding activity were pooled and concen- 
trated. The specificity of NF-xB was examined by immunoblotting 
using specific antiserum [12] and electrophoretic mobility shift assay 
(EMSA) using the tcB DNA probe [7,8]. 
2.3. Electrophoretic mobility shift assay ( EMSA ) 
The DNA binding activity was examined by EMSA using the specific 
1¢B DNA probe as previously described [7,8]. The t¢B sequence was 
taken from the human immunodeficiency virus long terminal repeat 
(HIV-LTR) [8]. The sequences ofthe xB wild-type and mutant oligonu- 
cleotides are as follows: 
Wild type xB (wtcB): 
5' TTTCTAGGGACTTTCCGCCTGGGGACTTTCCAG 3' (p lus s t rand)  
3 ' GATCCCTGAAAGGCGGACCCCTGAAAGGTCTTT 5 ' (minus  s t rand)  
Mutant s:B (mxB): 
5' TTTCTACTCACTTTCCGCTGCTCACTTTCCAG 3 ' (p lus s t rand)  
3 ' GATGAGTGAAAGGCGACGAGTGAAAGGTCTTT 5' (minus  s t rand)  
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The three T's were added to each oligonucleotide s quence for end 
labeling by Klenow DNA polymerase (Takara Biomedicals, Japan) and 
[~-32P]dATP (3000 Ci/mmol, ICN Pharmaceuticals Inc., USA). The 
labeled DNA probe was purified by passing it through a gel-filtration 
column (Quick Spin Column Sephadex G-25; Boehringer Mannheim, 
Germany) according to the instructions provided by the manufacturer. 
Binding reactions of the DNA probe with protein were performed 
at 30°C for 10 , in  in a total volume of 10 ~tl of buffer containing 22 
mM HEPES-KOH (pH 7.9), 80 mM KCI, 5% (v/v) glycerol, 0.1% 
Nonidet P-40, 1 mM dithiothreitol (DTT), 1 mM phenylmethysulfonyl 
fluoride (PMSF), 1/lg poly(dl~lC), 2/.tg tRNA and 0.1 ng (20,000- 
30,000 cpm) of the labeled xB DNA probe. The DNA-protein com- 
plexes were resolved in non-denaturing 6% polyacrylamide gels. Elec- 
trophoresis was performed in 0.5× TBE buffer (4.5 mM Tris, 4.5 mM 
boric acid, 0.1 mM EDTA, pH 8.0) at 4°C. 
For the competition experiment, 50-fold molar excess of unlabeled 
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Fig. 1. (A) NF-xB-DNA binding measured by EMSA. Fractions eluted from a DEAE column were incubated with 10 pl buffer containing 
radiolabeled HIV-LTR oligonucleotide. The samples were analyzed by 6% non-denaturing PAGE. The filled arrowhead indicates the NF-xB DNA 
complexes, while the open arrowhead indicates the free probe. *Indicates unspecific band. (B) Mutant (lane 3) and wild-type (lane 4) xB oligonucle- 
otide in the presence of 50-fold excess labeled DNA were preincubated with purified protein on ice for 5 rain before adding reaction buffer. The 
wild-type xB oligonucleotide, but not the mutant ype, abolished the NF-xB-DNA binding, indicating that the band represents sequence-specific 
binding. Lane 1, distilled water was added instead ofmxB and wxB. (C) Western blotting assay. A protein sample was separated by 5-20% SDS-PAGE 
and was transferred overnight at 4°C to a polyvinylidene difluoride (PVDF) membrane using buffer containing 20 mM Tris (pH 7.9), 15% methanol 
and 0.05% SDS. After washing with TBS (0.05% Tween 20), the membrane was blocked with 80% BlockAce (Yukijirushi Inc., Sapporo, Japan) and 
1% gelatin for 8 h at 4°C, and subsequently incubated with anti-NF4cB antibody (1 : 500) reconstituted with 10% BlockAce for 2 h at room temperature 
and ! h at 4°C with gently shaking. After washing with TBS, the blot was incubated with donkey anti-rabbit PHA (1 : 500) for 1 h at room temperature. 
The specific antigen antibody reaction was visualized using the ECL detection system (Amersham, Sweden). For the determination f molecular 
weight a rainbow marker was used. 
(.__ 
HIV wild-type xB or its mutant xB DNA was preincubated with the 
protein on ice for 5 min before adding the radioactive probe. After 
electrophoresis, gels were dried under vacuum and autoradiographed 
with Kodak T-Mat films (Eastman Kodak Co., Rochester, NY) at 
-80°C. Radioactive bands were quantified on an AMBIS 4000 system 
(AMBIS Inc., San Diego, CA). 
For the treatment of NF-xB with heavy metals and chelating agents, 
the protein was incubated with the test reagent in the binding buffer on 
ice for 20 min before adding the radioactive probe. Stock solutions of 
oPA (100 mM) or auranofin (5 raM) were prepared in ethanol and 
diluted with double-distilled water just before use. Control samples for 
these two reagents were likewise prepared in the same concentration f 
ethanol. All tests were performed at least three times which revealed 
consistent results. 
3. Results 
3.1. Preparation and identification of the nuclear NF4cB 
Protein was purified as described in section 2. Nuclear 
NF- tcB-DNA binding activity was detected by EMSA using the 
radiolabeled xB DNA probe (Fig. 1A). The specificity of NF-  
tcB activity was confirmed by DNA competit ion experiments 
using excess amount  of unlabeled double-stranded xB DNA 
(both wild-type and mutant)  (Fig. 1B). The Western blotting 
technique was applied to identify NF-xB protein using a spe- 
cific ant ibody [12] (Fig. 1C). F rom these observations, we con- 
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Fig. 2. Nuclear extract was preincubated with (A) gold compounds, (B) counter anions, and (C) other heavy metals, before being incubated with 
radiolabeled xB. Samples were analyzed by EMSA at the final concentrations of heavy metals and counter anions indicated. 
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firmed that the ~cB-DNA binding was due to the activity of 
NF-xB. 
3.2. Effects of goM compounds on DNA binding of NF-tcB 
NF-lcB was preincubated with various concentrations of gold 
compounds prior to addition of the radiolabeled xB probe. 
Among the gold compounds tested, AuTG showed the most 
effective inhibition of the protein-DNA binding while other 
gold compounds exhibited less inhibition in vitro (Fig. 2A). 
Au(I) appeared to have higher reactivity than Au(III). Al- 
though auranofin contains Au(I), it did not efficiently inhibit 
the binding, probably because of its lower solubility in water. 
Since treatment with counter anions alone, thiomalate or 
thioglucose, did not show such inhibition (Fig. 2B), this activity 
is considered to be due to the action of gold ion. This effect of 
Au(I) was obtained in the presence of 1 mM DTT, suggesting 
that oxidation by gold predominantly occurs at the thioate 
group of NF-~cB rather than DTT. 
We then investigated whether other heavy metals have the 
same effects as that of gold. Results in Fig. 2C show that, 
although Zn 2+ could slightly increase the binding activity at 
100 ktM, it inhibited the binding at concentrations higher than 
500/IM, presumably due to the binding of excess zinc ions to 
other sensitive cysteins in the protein (Fig. 2C, lanes 3-6). A 
similar effect of zinc was also described in Zabel et al. [13]. On 
the other hand, Mg 2+ and Mn 2+ appeared to have little effect 
on the binding (Fig. 2C). It is worth noting that the order of 
such effects corresponded to the affinities for thiols, or oxida- 
tion potentials, of these heavy metals [14,15]. 
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Fig. 2 (continued). 
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Fig. 3. (A) oPA, EDTA, EGTA and DPA were preincubated with protein on ice for 20 min before adding radiolabeled xB. Samples were analyzed 
by EMSA. (B) The gel was dried and quantified by STL-4000 and plotted as percent activity of protein-DNA binding of the control lane. Values 
represent he mean of three independent experiments. 
3.3. Combination of  AuTG, Zn 2÷ and oPA at limited 
concentrations can restore NF-tcB-DNA binding activity 
It was previously reported that the DNA binding of NF-xB 
requires Zn z+ [13], although NF-xB is not known to contain a 
typical zinc finger motif [16]. We first examined effects of the 
different chelating agents on the protein-DNA interaction. 
Among the chelators examined, only oPA showed a concentra- 
tion-dependent inhibition of NF-xB-DNA binding activity 
(Fig. 3B). Other chelators, even at a concentration of 4.0 mM, 
failed to show such an inhibitory effect (Fig. 3A). 
We then asked if gold inhibits the NF-xB activity by replac- 
ing with zinc ion or by oxidizing the thiolates on the NF-xB 
molecule without binding to them. The following experiments 
were thus carried out in an attempt o distinguish between these 
two possibilities. In Fig. 4A, NF-xB was preincubated with 
both oPA and AuTG and subsequently examined for the effect 
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of gold. As shown in Fig. 4A, AuTG could restore the binding 
at a concentration equivalent to oPA. These findings suggest 
that Au(I) could replace Zn 2+ associated with oPA and the 
released Zn 2+ could then reassociate with NF-xB. Therefore, it 
is likely that gold would not associate with NF-xB but rather 
oxidize the thiolate ions on NF-xB into disulfides (see section 
4 for the possible mechanism). In Fig. 4B, NF-KB was preincu- 
bated with both oPA and ZnCI  2. The results showed a similar 
pattern as in Fig. 4A, although the restoration of binding by 
Zn 2+ appeared to be more efficient. For example, the binding 
activity upon treatment with oPA (higher than 0.5 mM) and 
Zn 2+ was even enhanced as much as two times (Fig. 4B, lanes 
10, 15, 20). These results again confirmed that Zn 2+ is an essen- 
tial component of NF-xB activity. At higher concentrations of
AuTG or ZnCI2 the DNA binding activity was suppressed (Fig. 
4A, lanes 6, 11, 16 and 21; Fig. 4B, lanes 6, 11, 16 and 21) as 
also noticed in Fig. 2. In Fig. 4C, NF-xB was preincubated with 
both DPA and AuTG, but no effect was observed. DPA ap- 
peared to block the inhibitory effect of AuTG on NF-xB activ- 
ity, indicating the possible interaction between Au(I) and DPA. 
4. Discussion 
The results presented here demonstrate hat gold compounds 
can inhibit the DNA binding of NF-xB in vitro. Among the 
various gold compounds, AuTG showed the most effective 
inhibition of the DNA binding of NF-xB. It is known that 
Au(I) is the therapeutically active component of gold com- 
pounds in the treatment of RA and that the counter anion 
might provide some additional benefits [17]. It is suggested that 
the different inhibitory action of gold compounds on NF-JcB 
(Fig. 2A) might be due to the difference in the ability of their 
counter anions to release Au(I) since counter anions alone did 
not show any effect. Similar effects of gold compounds in inhib- 
iting DNA binding of glucocorticoid receptor and progesterone 
receptor have been reported elsewhere [18,19]. Zabel et al. [13] 
reported that NF-xB specifically requires Zn 2+ for optimal 
DNA binding. Our observations revealed that addition of Zn 2+ 
facilitated the DNA binding (Fig. 2C, lane 4). We also observed 
that the effects of heavy metals in inhibiting the NF-xB DNA 
binding were in accord with the rank order of oxidation poten- 
tial of these metal ions [14,15] (Fig. 2A and B). We observed 
that Au(I) inhibited the DNA binding activity of NFxB by 
oxidizing the Zn2+-associated thiols and not by replacing them; 
this was clearly demonstrated in Fig. 4A in which withdrawal 
of Zn 2÷ abolished the DNA binding, and the subsequent addi- 
tion of AuTG restored the binding. It is conceivable that the 
stability of the Au-oPA complex is much higher than that of 
Zn-oPA [15]; therefore, addition of a small amount of Au(I) 
could release Zn 2+ from the Zn-oPA complex, thus generating 
the active form of NF-IcB, the NF-~B~n complex. Therefore, 
the actions of gold can be explained by its strong oxidative 
potential over the zinc ions associated with NF-xB. 
The redox regulation of NF-xB of its DNA binding activity 
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Fig. 4. Nuclear extract was preincubated with both (A) oPA and AUTO, (B) oPA and ZnC12, or (C) DPA and AuTG, at the indicated concentrations 
and subjected to gel-retardation with radiolabeled ~cB. After autoradiography, theradioactivity was quantified by STL-4000 and plotted as percent 
activity of NF-IcB-DNA binding of the control lane. 
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Fig. 4 (continued). 
has been demonstrated [7,20]. When the cysteineresidues of 
NF-xB were oxidized by diamide or modified by N-ethyl- 
maleimide (NEM), the DNA binding activity of NF-xB was 
abrogated [7,20]. Involvement of cysteine residues in the NF- 
xB-DNA binding was confirmed by the site-directed mut- 
agenesis experiment in which Cys 62 of p50 was shown to be 
critical [20]. It was previously postulated that the therapeutic 
effects of gold salts might be due to the inhibition of sulfhydryl 
systems [17]. Together with the present results, we assume that 
the redox mechanism ight also be involved in the inhibitory 
effects of gold compounds on NF-tcB-DNA binding. Since 
gold ion did not appear to exert he NF-tcB inhibition by direct 
binding (Fig. 4), it is likely that Au(I) can oxidize the thiolate 
anions on the NF-IcB molecule into disulfides and thus abro- 
gate the DNA binding activity, considering the higher oxida- 
tion potential of Au(I) over Zn 2+ (Fig. 5). 
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Fig. 5. Oxidation of NF-xB by gold cation. The active DNA binding 
form of NF-xB is hypothesized to contain zinc ions. When gold com- 
pound is added, Au(I) can take the electron from the thiolate anions 
due to its higher oxidation potential compared to that of Zn 2÷. Thus, 
Au(I) eventually oxidizes the thiolate anions of NF-xB into disulfide. 
The oxidation of NF-lcB abolishes the DNA binding activity [7,8]. 
In conclusion, our findings suggest hat Zn 2+ is an essential 
component for the NF-tcB activity, and that one of the mecha- 
nisms of gold compounds might be through the inhibition of 
the DNA binding activity of NF-IcB by redox mechanism. The 
observed concentrations of AuTG required for in vitro inhibi- 
tion of NF -xB-DNA binding (less than 100 ¢tM) are compara- 
ble to the peak serum gold concentration i treated patients 
(3040 ¢tM) [11]. It should be noted that NF-xB plays a pivotal 
role in the cytokine network involved in the pathogenesis of 
RA, and even minimal or partial inhibition of its activity might 
elicit a substantial effect on inflammatory processes. It is also 
possible that gold compounds affect multiple transcription fac- 
tors in addition to NF-xB [19]. Our attempt o examine the 
effects of gold compounds in cell culture systems is underway. 
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